Kidney Outcomes in Transthyretin Amyloid Cardiomyopathy

Posted by Jim Michalski

JAMA Cardiology

EMBARGOED FOR RELEASE: 12:50 P.M. (ET), SUNDAY, NOVEMBER 17, 2024

Media advisory: The full study is linked to this news release. This study is being presented at the American Heart Association’s Scientific Sessions 2024.

Embed this link to provide your readers free access to the full-text article This link will be live at the embargo time https://jamanetwork.com/journals/jamacardiology/fullarticle/10.1001/jamacardio.2024.4578?guestAccessKey=c1d676ce-acb0-403b-a519-25efb8f6e6c3&utm_source=for_the_media&utm_medium=referral&utm_campaign=ftm_links&utm_content=tfl&utm_term=111724

 

About The Study: In this retrospective cohort study, decline in kidney function was frequent in patients with transthyretin amyloid cardiomyopathy (ATTR-CM) and was consistently associated with an increased risk of mortality, even after adjusting for established markers of worsening ATTR-CM. eGFR decline represents an independent marker of ATTR-CM disease progression that could guide treatment optimization in clinical practice. 

Corresponding Author: To contact the corresponding author, Marianna Fontana, MD, PhD, email m.fontana@ucl.ac.uk.

 

(doi:10.1001/jamacardio.2024.4578)

Editor’s Note: Please see the article for additional information, including other authors, author contributions and affiliations, conflicts of interest and financial disclosures, and funding and support.

#  #  #

For more information, contact JAMA Network Media Relations at 312-464-JAMA (5262) or email media relations.

No Comments

Filed under:

Hospitalization Following Outpatient Diagnosis of RSV in Adults

Posted by Jim Michalski

JAMA Network Open

EMBARGOED FOR RELEASE: 11 A.M. ET, TUESDAY, NOVEMBER 19, 2024

Media advisory: The full study is linked to this news release.

Embed this link to provide your readers free access to the full-text article This link will be live at the embargo time http://jamanetwork.com/journals/jamanetworkopen/fullarticle/10.1001/jamanetworkopen.2024.46010?utm_source=For_The_Media&utm_medium=referral&utm_campaign=ftm_links&utm_term=111924

About JAMA Network Open: JAMA Network Open is an online-only open access general medical journal from the JAMA Network. On weekdays, the journal publishes peer-reviewed clinical research and commentary in more than 40 medical and health subject areas. Every article is free online from the day of publication. 

 

About The Study: In this cohort study of adults with outpatient medically attended-respiratory syncytial virus (RSV) infections from 3 large deidentified U.S. databases across 6 RSV seasons, approximately 1 in 20 adults experienced all-cause hospitalization within 28 days. The results of this study highlight the public health need for RSV prevention and treatment. 

Corresponding Author: To contact the corresponding author, Joshua T. Swan, PharmD, MPH, email swan.joshua@gmail.com.

 

(doi:10.1001/jamanetworkopen.2024.46010)

Editor’s Note: Please see the article for additional information, including other authors, author contributions and affiliations, conflict of interest and financial disclosures, and funding and support.

#  #  #

For more information, contact JAMA Network Media Relations at 312-464-JAMA (5262) or email media relations.

No Comments

Filed under:

Oral Muvalaplin for Lowering of Lipoprotein(a)

Posted by Jim Michalski

JAMA

EMBARGOED FOR RELEASE: 2:52 P.M. ET, MONDAY, NOVEMBER 18, 2024

Media advisory: The full study is linked to this news release. This study is being presented at the American Heart Association’s Scientific Sessions 2024.

Embed this link to provide your readers free access to the full-text article This link will be live at the embargo time https://jamanetwork.com/journals/jama/fullarticle/10.1001/jama.2024.24017?guestAccessKey=f849b8a2-374c-4de8-87cc-7ee02b84e5f9&utm_source=For_The_Media&utm_medium=referral&utm_campaign=ftm_links&utm_content=tfl&utm_term=111824

 

About The Study: Muvalaplin, an oral small molecule lipoprotein(a) inhibitor, reduced lipoprotein(a) measured using intact lipoprotein(a) and apolipoprotein(a)-based assays and was well tolerated. The effect of muvalaplin on cardiovascular events requires further investigation. 

Corresponding Author: To contact the corresponding author, Stephen J. Nicholls, MBBS, PhD, email stephen.nicholls@monash.edu.

 

(doi:10.1001/jama.2024.24017)

Editor’s Note: Please see the article for additional information, including other authors, author contributions and affiliations, conflict of interest and financial disclosures, and funding and support.

#  #  #

For more information, contact JAMA Network Media Relations at 312-464-JAMA (5262) or email media relations.

No Comments

Filed under:

Active Surveillance or Watchful Waiting for Intermediate-Risk Prostate Cancer, 2010-2020

Posted by Jim Michalski

JAMA

EMBARGOED FOR RELEASE: 11 A.M. ET, WEDNESDAY, NOVEMBER 20, 2024

Media advisory: The full study is linked to this news release.

Embed this link to provide your readers free access to the full-text article This link will be live at the embargo time https://jamanetwork.com/journals/jama/fullarticle/10.1001/jama.2024.20580?guestAccessKey=076ede4e-9f05-459b-aeef-3f311f77ce82&utm_source=For_The_Media&utm_medium=referral&utm_campaign=ftm_links&utm_content=tfl&utm_term=112024

 

About The Study: Amid a rising trend of conservative management for prostate cancer, this study found a significant increase in initial active surveillance and watchful waiting for intermediate–risk prostate cancer between 2010 and 2020. This corresponds with evidence of favorable longer-term outcomes and improvements in staging imaging and risk stratification.

Corresponding Author: To contact the corresponding author, Michael S. Leapman, MD, MHS, email michael.leapman@yale.edu.

 

(doi:10.1001/jama.2024.20580)

Editor’s Note: Please see the article for additional information, including other authors, author contributions and affiliations, conflict of interest and financial disclosures, and funding and support.

#  #  #

For more information, contact JAMA Network Media Relations at 312-464-JAMA (5262) or email media relations.

No Comments

Filed under:

Pulmonary Vein Isolation With Optimized Linear Ablation vs Pulmonary Vein Isolation Alone for Persistent AF

Posted by Jim Michalski

JAMA

EMBARGOED FOR RELEASE: 10:45 A.M. ET, MONDAY, NOVEMBER 18, 2024

Media advisory: The full study and editorial are linked to this news release. This study is being presented at the American Heart Association’s Scientific Sessions 2024.

Embed this link to provide your readers free access to the full-text article This link will be live at the embargo time https://jamanetwork.com/journals/jama/fullarticle/10.1001/jama.2024.24438?guestAccessKey=a09e242c-4c4a-40e5-82a6-c7368fadfa15&utm_source=For_The_Media&utm_medium=referral&utm_campaign=ftm_links&utm_content=tfl&utm_term=111824

 

About The Study: Among patients with persistent atrial fibrillation, linear ablation combined with ethanol infusion of the vein of Marshall in addition to pulmonary vein isolation significantly improved freedom from atrial arrhythmias within 12 months compared with pulmonary vein isolation alone. 

Corresponding Authors: To contact the corresponding authors, email Changsheng Ma, MD, (chshma@vip.sina.com) and Chenyang Jiang, MD, (jiangchenyangmail@163.com).

 

(doi:10.1001/jama.2024.24438)

Editor’s Note: Please see the article for additional information, including other authors, author contributions and affiliations, conflict of interest and financial disclosures, and funding and support.

#  #  #

For more information, contact JAMA Network Media Relations at 312-464-JAMA (5262) or email media relations.

No Comments

Filed under:

Trends in Gender, Racial, and Ethnic Representation Among US Neurology Faculty

Posted by Jim Michalski

Embed this link to provide your readers free access to the full-text article This link will be live at the embargo time https://jamanetwork.com/journals/jamaneurology/fullarticle/10.1001/jamaneurol.2024.3909?guestAccessKey=99bdf5e0-9abc-40a3-b41d-659ff7405c3c&utm_source=For_The_Media&utm_medium=referral&utm_campaign=ftm_links&utm_content=tfl&utm_term=111824

No Comments

Filed under:

Next-Generation Multitarget Stool DNA vs Fecal Immunochemical Test in Colorectal Cancer Screening

Posted by Jim Michalski

Embed this link to provide your readers free access to the full-text article This link will be live at the embargo time https://jamanetwork.com/journals/jamainternalmedicine/fullarticle/10.1001/jamainternmed.2024.6149?guestAccessKey=7d70351f-adab-4941-bc7e-5601af3ee891&utm_source=For_The_Media&utm_medium=referral&utm_campaign=ftm_links&utm_content=tfl&utm_term=111824

No Comments

Filed under:

Zerlasiran—A Small-Interfering RNA Targeting Lipoprotein(a)

Posted by Jim Michalski

JAMA

EMBARGOED FOR RELEASE: 2:40 P.M. ET, MONDAY, NOVEMBER 18, 2024

Media advisory: The full study is linked to this news release. This study is being presented at the American Heart Association’s Scientific Sessions 2024.

Embed this link to provide your readers free access to the full-text article This link will be live at the embargo time https://jamanetwork.com/journals/jama/fullarticle/10.1001/jama.2024.21957?guestAccessKey=f0dc38dc-63c0-41f5-a731-77e1e406f2ab&utm_source=For_The_Media&utm_medium=referral&utm_campaign=ftm_links&utm_content=tfl&utm_term=111824

 

About The Study: Zerlasiran, a small-interfering RNA targeting hepatic synthesis of apolipoprotein(a), was well-tolerated and reduced time-averaged lipoprotein(a) concentration by more than 80% during 36 weeks of treatment in patients with atherosclerotic cardiovascular disease. 

Corresponding Author: To contact the corresponding author, Steven E. Nissen, MD, email nissens@ccf.org.

 

(doi:10.1001/jama.2024.21957)

Editor’s Note: Please see the article for additional information, including other authors, author contributions and affiliations, conflict of interest and financial disclosures, and funding and support.

#  #  #

For more information, contact JAMA Network Media Relations at 312-464-JAMA (5262) or email media relations.

No Comments

Filed under:

Prevalence of Cardiovascular-Kidney-Metabolic Syndrome Stages by Social Determinants of Health

Posted by Jim Michalski

JAMA Network Open

EMBARGOED FOR RELEASE: 11 A.M. ET, MONDAY, NOVEMBER 18, 2024

Media advisory: The full study and commentary are linked to this news release.

Embed this link to provide your readers free access to the full-text article This link will be live at the embargo time http://jamanetwork.com/journals/jamanetworkopen/fullarticle/10.1001/jamanetworkopen.2024.45309?utm_source=For_The_Media&utm_medium=referral&utm_campaign=ftm_links&utm_term=111824

About JAMA Network Open: JAMA Network Open is an online-only open access general medical journal from the JAMA Network. On weekdays, the journal publishes peer-reviewed clinical research and commentary in more than 40 medical and health subject areas. Every article is free online from the day of publication. 

 

About The Study: The results of this study suggest a disproportionate burden of cardiovascular-kidney-metabolic syndrome by social determinants of health and sex. These findings highlight the need to address inequities in cardiovascular-kidney-metabolic syndrome through targeted interventions. 

Corresponding Author: To contact the corresponding author, Jie Guo, PhD, email jie.guo@ki.se.

 

(doi:10.1001/jamanetworkopen.2024.45309)

Editor’s Note: Please see the article for additional information, including other authors, author contributions and affiliations, conflict of interest and financial disclosures, and funding and support.

#  #  #

For more information, contact JAMA Network Media Relations at 312-464-JAMA (5262) or email media relations.

No Comments

Filed under:

Semaglutide Eligibility Across All Current Indications for US Adults

Posted by Jim Michalski

JAMA Cardiology

EMBARGOED FOR RELEASE: 2:30 P.M. (ET), MONDAY, NOVEMBER 18, 2024

Media advisory: The full study is linked to this news release. This study is being presented at the American Heart Association’s Scientific Sessions 2024.

Embed this link to provide your readers free access to the full-text article This link will be live at the embargo time https://jamanetwork.com/journals/jamacardiology/fullarticle/10.1001/jamacardio.2024.4657?guestAccessKey=baa342ec-8c33-4211-98eb-b1ec08d802eb&utm_source=for_the_media&utm_medium=referral&utm_campaign=ftm_links&utm_content=tfl&utm_term=111824

 

About The Study: A total of nearly 137 million adults, representing more than half of all U.S. adults, are eligible for semaglutide therapy. This exceeds the number of adults eligible for statins (approximately 82 million), currently the most prescribed pharmaceuticals among U.S. adults. 

Corresponding Author: To contact the corresponding author, Dhruv S. Kazi, MD, MS, email dkazi@bidmc.harvard.edu.

 

(doi:10.1001/jamacardio.2024.4657)

Editor’s Note: Please see the article for additional information, including other authors, author contributions and affiliations, conflicts of interest and financial disclosures, and funding and support.

#  #  #

For more information, contact JAMA Network Media Relations at 312-464-JAMA (5262) or email media relations.

No Comments

Filed under:

Early Adoption of Sodium-Glucose Cotransporter-2 Inhibitor in Patients Hospitalized With Heart Failure With Mildly Reduced or Preserved Ejection Fraction

Posted by Jim Michalski

JAMA Cardiology

EMBARGOED FOR RELEASE: 11:30 A.M. (ET), MONDAY, NOVEMBER 18, 2024

Media advisory: The full study is linked to this news release. This study is being presented at the American Heart Association’s Scientific Sessions 2024.

Embed this link to provide your readers free access to the full-text article This link will be live at the embargo time https://jamanetwork.com/journals/jamacardiology/fullarticle/10.1001/jamacardio.2024.4489?guestAccessKey=035fde61-fae7-4073-90da-14cd7c2a712d&utm_source=for_the_media&utm_medium=referral&utm_campaign=ftm_links&utm_content=tfl&utm_term=111824

 

About The Study: In this study of discharge prescription of a sodium-glucose cotransporter-2 inhibitor (SGLT2i) among patients hospitalized for heart failure, prescription rates increased substantially within 2 years after publication of clinical trial evidence documenting benefit, although considerable variation in rates was found, highlighting the need to understand strategies used by higher prescribing centers to increase SGLT2i adoption.

Corresponding Author: To contact the corresponding author, Mohammad Abdel Jawad, MD, email abdeljawadmd@gmail.com.

 

(doi:10.1001/jamacardio.2024.4489)

Editor’s Note: Please see the article for additional information, including other authors, author contributions and affiliations, conflicts of interest and financial disclosures, and funding and support.

#  #  #

For more information, contact JAMA Network Media Relations at 312-464-JAMA (5262) or email media relations.

No Comments

Filed under:

Evaluating Performance and Agreement of Coronary Heart Disease Polygenic Risk Scores

Posted by Jim Michalski

JAMA

EMBARGOED FOR RELEASE: 2:30 P.M. ET, SATURDAY, NOVEMBER 16, 2024

Media advisory: The full study and editorial are linked to this news release. This study is being presented at the American Heart Association’s Scientific Sessions 2024.

Embed this link to provide your readers free access to the full-text article This link will be live at the embargo time https://jamanetwork.com/journals/jama/fullarticle/10.1001/jama.2024.23784?guestAccessKey=5f0c3425-c031-4f57-8d41-a33a2be65d21&utm_source=For_The_Media&utm_medium=referral&utm_campaign=ftm_links&utm_content=tfl&utm_term=111624

 

About The Study: Coronary heart disease polygenic risk scores that performed similarly at the population level demonstrated highly variable individual-level estimates of risk. Recognizing that coronary heart disease polygenic risk scores may generate incongruent individual-level risk estimates, effective clinical implementation will require refined statistical methods to quantify uncertainty and new strategies to communicate this uncertainty to patients and clinicians. 

Corresponding Author: To contact the corresponding author, Scott M. Damrauer, MD, email Scott.Damrauer@pennmedicine.upenn.edu.

 

(doi:10.1001/jama.2024.23784)

Editor’s Note: Please see the article for additional information, including other authors, author contributions and affiliations, conflict of interest and financial disclosures, and funding and support.

#  #  #

For more information, contact JAMA Network Media Relations at 312-464-JAMA (5262) or email media relations.

No Comments

Filed under:

Heart Failure in Zero Gravity— External Constraint and Cardiac Hemodynamics

Posted by Jim Michalski

JAMA Cardiology

EMBARGOED FOR RELEASE: 3 P.M. (ET), SATURDAY, NOVEMBER 16, 2024

Media advisory: The full study is linked to this news release. This study is being presented at the American Heart Association’s Scientific Sessions 2024.

Embed this link to provide your readers free access to the full-text article This link will be live at the embargo time https://jamanetwork.com/journals/jamacardiology/fullarticle/10.1001/jamacardio.2024.4596?guestAccessKey=cc31323f-05a3-4b6b-a94e-db97024524f0&utm_source=for_the_media&utm_medium=referral&utm_campaign=ftm_links&utm_content=tfl&utm_term=111624

 

About The Study: In this case series study, pulmonary artery systolic, diastolic, and mean pressures of 2 participants with obesity and heart failure with preserved ejection fraction were measured at zero gravity during parabolic flight to assess the effect of external constraint on left ventricular filling pressures. 

Corresponding Author: To contact the corresponding author, Benjamin D. Levine, MD, email benjaminlevine@texashealth.org.

 

 (doi:10.1001/jamacardio.2024.4596)

Editor’s Note: Please see the article for additional information, including other authors, author contributions and affiliations, conflicts of interest and financial disclosures, and funding and support.

#  #  #

For more information, contact JAMA Network Media Relations at 312-464-JAMA (5262) or email media relations.

No Comments

Filed under:

Interpreting Population Mean Treatment Effects in the Kansas City Cardiomyopathy Questionnaire

Posted by Jim Michalski

JAMA Cardiology

EMBARGOED FOR RELEASE: 12 P.M. (ET), FRIDAY, NOVEMBER 15, 2024

Media advisory: The full study and editor’s note are linked to this news release. This study is being presented at the AHA’s Quality of Care and Outcomes Research Early Career Investigator Abstract Award Competition.

Embed this link to provide your readers free access to the full-text article This link will be live at the embargo time https://jamanetwork.com/journals/jamacardiology/fullarticle/10.1001/jamacardio.2024.4470?guestAccessKey=fe8933ab-b2a5-4564-918c-b64dc5a29686&utm_source=for_the_media&utm_medium=referral&utm_campaign=ftm_links&utm_content=tfl&utm_term=111524

 

About The Study: Inferences about clinical impacts based on population-level mean treatment effects may be misleading, since even small between-group differences may reflect clinically important treatment benefits for individual patients. Results of this study suggest that clinical trials should explicitly describe the distributions of Kansas City Cardiomyopathy Questionnaire change at the patient level within treatment groups to support the clinical interpretation of their results. 

Corresponding Author: To contact the corresponding author, John Spertus, MD, MPH, email spertusj@umkc.edu.

 

(doi:10.1001/jamacardio.2024.4470)

Editor’s Note: Please see the article for additional information, including other authors, author contributions and affiliations, conflicts of interest and financial disclosures, and funding and support.

#  #  #

For more information, contact JAMA Network Media Relations at 312-464-JAMA (5262) or email media relations.

No Comments

Filed under:

Artemisinin Partial Resistance in Ugandan Children With Complicated Malaria

Posted by Jim Michalski

JAMA

EMBARGOED FOR RELEASE: 9 A.M. ET, THURSDAY, NOVEMBER 14, 2024

Media advisory: The full study and editorial are linked to this news release. This study is being presented at the American Society of Tropical Medicine and Hygiene Annual Meeting.

Embed this link to provide your readers free access to the full-text article This link will be live at the embargo time https://jamanetwork.com/journals/jama/fullarticle/10.1001/jama.2024.22343?guestAccessKey=e1d2a9e9-6787-4bb6-8a5e-012c4e656527&utm_source=For_The_Media&utm_medium=referral&utm_campaign=ftm_links&utm_content=tfl&utm_term=111424

 

About The Study: This study found artemisinin partial resistance in Ugandan children with complicated malaria associated with the Pfkelch13 A675V variation and also found suboptimal 28-day efficacy of parenteral artesunate followed by oral artemether/lumefantrine therapy. 

Corresponding Author: To contact the corresponding author, Chandy C. John, MD, MS, email chjohn@iu.edu.

 

(doi:10.1001/jama.2024.22343)

Editor’s Note: Please see the article for additional information, including other authors, author contributions and affiliations, conflict of interest and financial disclosures, and funding and support.

#  #  #

For more information, contact JAMA Network Media Relations at 312-464-JAMA (5262) or email media relations.

No Comments

Filed under:

Trends in Hospitalizations and Liver Transplants Associated With Alcohol-Induced Liver Disease

Posted by Jim Michalski

JAMA

EMBARGOED FOR RELEASE: 11 A.M. ET, THURSDAY, NOVEMBER 14, 2024

Media advisory: The full study is linked to this news release.

Embed this link to provide your readers free access to the full-text article This link will be live at the embargo time https://jamanetwork.com/journals/jama/fullarticle/10.1001/jama.2024.21503?guestAccessKey=4a087071-8c61-45b4-969b-687fa06537f0&utm_source=For_The_Media&utm_medium=referral&utm_campaign=ftm_links&utm_content=tfl&utm_term=111424

 

About The Study: This study found significant rate increases for alcohol-induced liver disease-related hospitalizations and liver transplants across sex and age groups between 2005 and 2021. Although older males had the highest absolute increases, the greatest relative increases occurred in younger individuals, particularly females.

Corresponding Author: To contact the corresponding author, Michele Molinari, MD, MSc, email molinarim@upmc.edu.

 

(doi:10.1001/jama.2024.21503)

Editor’s Note: Please see the article for additional information, including other authors, author contributions and affiliations, conflict of interest and financial disclosures, and funding and support.

#  #  #

For more information, contact JAMA Network Media Relations at 312-464-JAMA (5262) or email media relations.

No Comments

Filed under:

Spinal Cord Stimulation vs Medical Management for Chronic Back and Leg Pain

Posted by Jim Michalski

JAMA Network Open

EMBARGOED FOR RELEASE: 11 A.M. ET, THURSDAY, NOVEMBER 14, 2024

Media advisory: The full study is linked to this news release.

Embed this link to provide your readers free access to the full-text article This link will be live at the embargo time http://jamanetwork.com/journals/jamanetworkopen/fullarticle/10.1001/jamanetworkopen.2024.44608?utm_source=For_The_Media&utm_medium=referral&utm_campaign=ftm_links&utm_term=111424

About JAMA Network Open: JAMA Network Open is an online-only open access general medical journal from the JAMA Network. On weekdays, the journal publishes peer-reviewed clinical research and commentary in more than 40 medical and health subject areas. Every article is free online from the day of publication. 

 

About The Study: This systematic review and network meta-analysis found that spinal cord stimulation therapies for treatment of chronic pain in back and/or lower extremities were associated with greater improvements in pain compared with conventional medical management. These findings highlight the potential of spinal cord stimulation therapies as an effective and valuable option in chronic pain management.

Corresponding Author: To contact the corresponding author, Konstantinos Soulanis, M.Sc., email konstantinos.soulanis@iqvia.com.

 

(doi:10.1001/jamanetworkopen.2024.44608)

Editor’s Note: Please see the article for additional information, including other authors, author contributions and affiliations, conflict of interest and financial disclosures, and funding and support.

#  #  #

For more information, contact JAMA Network Media Relations at 312-464-JAMA (5262) or email media relations.

No Comments

Filed under:

Burden of RSV–Associated Hospitalizations in US Adults, October 2016 to September 2023

Posted by Jim Michalski

JAMA Network Open

EMBARGOED FOR RELEASE: 11 A.M. ET, WEDNESDAY, NOVEMBER 13, 2024

Media advisory: The full study is linked to this news release.

Embed this link to provide your readers free access to the full-text article This link will be live at the embargo time https://jamanetwork.com/journals/jamanetworkopen/fullarticle/10.1001/jamanetworkopen.2024.44756?guestAccessKey=d83f9e46-0b9d-4334-872c-25b398db5a43&utm_source=for_the_media&utm_medium=referral&utm_campaign=ftm_links&utm_content=tfl&utm_term=111324

About JAMA Network Open: JAMA Network Open is an online-only open access general medical journal from the JAMA Network. On weekdays, the journal publishes peer-reviewed clinical research and commentary in more than 40 medical and health subject areas. Every article is free online from the day of publication. 

 

About The Study: In this cross-sectional study of adults hospitalized with respiratory syncytial virus (RSV) before the 2023 introduction of RSV vaccines, RSV was associated with substantial burden of hospitalizations, ICU admissions, and in-hospital deaths in adults, with the highest rates occurring in adults 75 years or older. Increasing RSV vaccination of older adults has the potential to reduce associated hospitalizations and severe clinical outcomes.

Corresponding Author: To contact the corresponding author, Fiona P. Havers, MHS, MD, email fhavers@cdc.gov.

 

(doi:10.1001/jamanetworkopen.2024.44756)

Editor’s Note: Please see the article for additional information, including other authors, author contributions and affiliations, conflict of interest and financial disclosures, and funding and support.

#  #  #

For more information, contact JAMA Network Media Relations at 312-464-JAMA (5262) or email media relations.

No Comments

Filed under:

Transcranial Direct Current Stimulation Combined With Repetitive Transcranial Magnetic Stimulation for Depression

Posted by Jim Michalski

Embed this link to provide your readers free access to the full-text article This link will be live at the embargo time https://jamanetwork.com/journals/jamanetworkopen/fullarticle/10.1001/jamanetworkopen.2024.44306?guestAccessKey=1365ef92-cd83-4567-bc70-bdb46ceeb5b7&utm_source=for_the_media&utm_medium=referral&utm_campaign=ftm_links&utm_content=tfl&utm_term=111324

No Comments

Filed under:

Repurposing Semaglutide and Liraglutide for Alcohol Use Disorder

Posted by Jim Michalski

JAMA Psychiatry

EMBARGOED FOR RELEASE: 11 A.M. (ET), WEDNESDAY, NOVEMBER 13, 2024

Media advisory: The full study is linked to this news release.

Embed this link to provide your readers free access to the full-text article This link will be live at the embargo time https://jamanetwork.com/journals/jamapsychiatry/fullarticle/10.1001/jamapsychiatry.2024.3599?guestAccessKey=4bf50b14-c77f-4a44-9a4f-0b52c5fd0f9b&utm_source=for_the_media&utm_medium=referral&utm_campaign=ftm_links&utm_content=tfl&utm_term=111324

 

About The Study: Among patients with alcohol use disorder (AUD) and comorbid obesity/type 2 diabetes, the use of semaglutide and liraglutide were associated with a substantially decreased risk of hospitalization due to AUD. This risk was lower than that of officially approved AUD medications. Semaglutide and liraglutide may be effective in the treatment of AUD, and clinical trials are urgently needed to confirm these findings. 

Corresponding Author: To contact the corresponding author, Markku Lähteenvuo, MD, PhD, email markku.lahteenvuo@uef.fi.

 

(10.1001/jamapsychiatry.2024.3599)

Editor’s Note: Please see the article for additional information, including other authors, author contributions and affiliations, conflict of interest and financial disclosures, and funding and support.

#  #  #

For more information, contact JAMA Network Media Relations at 312-464-JAMA (5262) or email media relations.

No Comments

Filed under:

Grief-Specific Cognitive Behavioral Therapy vs Present-Centered Therapy

Posted by Jim Michalski

JAMA Psychiatry

EMBARGOED FOR RELEASE: 6:35 A.M. (ET), WEDNESDAY, NOVEMBER 13, 2024

Media advisory: The full study is linked to this news release. This study is being presented at the European Grief Conference.

Embed this link to provide your readers free access to the full-text article This link will be live at the embargo time https://jamanetwork.com/journals/jamapsychiatry/fullarticle/10.1001/jamapsychiatry.2024.3409?guestAccessKey=3d185cbf-392b-4f52-b17e-2b6d449a7aa9&utm_source=for_the_media&utm_medium=referral&utm_campaign=ftm_links&utm_content=tfl&utm_term=111324

 

About The Study: This randomized clinical trial demonstrates that cognitive behavioral therapy for prolonged grief was superior to present-centered therapy after treatment and at follow-up with regard to comorbid symptoms. Both treatments were shown to be effective and acceptable, showing the potential for dissemination and increasing patient choice. 

Corresponding Author: To contact the corresponding author, Rita Rosner, PhD, email rita.rosner@ku.de.

 

(10.1001/jamapsychiatry.2024.3409)

Editor’s Note: Please see the article for additional information, including other authors, author contributions and affiliations, conflict of interest and financial disclosures, and funding and support.

#  #  #

For more information, contact JAMA Network Media Relations at 312-464-JAMA (5262) or email media relations.

No Comments

Filed under:

Income-Related Disparities in Mortality Among Young Adults With Type 2 Diabetes

Posted by Alexandra Marusarz

JAMA Network Open

EMBARGOED FOR RELEASE: 11 A.M. (ET), TUESDAY, NOVEMBER 12, 2024

Media advisory: The full study is linked to this news release.

Embed this link to provide your readers free access to the full-text article This link will be live at the embargo time http://jamanetwork.com/journals/jamanetworkopen/fullarticle/10.1001/jamanetworkopen.2024.43918?utm_source=For_The_Media&utm_medium=referral&utm_campaign=ftm_links&utm_term=111224

About JAMA Network Open: JAMA Network Open is an online-only open access general medical journal from the JAMA Network. On weekdays, the journal publishes peer-reviewed clinical research and commentary in more than 40 medical and health subject areas. Every article is free online from the day of publication.

 

About The Study: In this cohort study of 1.2 million individuals ages 20 to 79 in South Korea, the risk of mortality with low income was most prominent among individuals with type 2 diabetes ages 20 to 39. These findings highlight the need for socioeconomic support to reduce income-related health disparities in younger individuals.

Corresponding authors: To contact the corresponding authors, email Sin Gon Kim, MD, PhD (k50367@korea.ac.kr) and Nam Hoon Kim, MD, PhD (pourlife@korea.ac.kr).

 

(doi: 10.1001/jamanetworkopen.2024.43918)

Editor’s Note: Please see the article for additional information, including other authors, author contributions and affiliations, conflict of interest and financial disclosures, and funding and support.

#  #  #

For more information, contact JAMA Network Media Relations at 312-464-JAMA (5262) or email media relations.

No Comments

Filed under:

Discontinuation of Glucagon-Like Peptide-1 Receptor Agonists

Posted by Jim Michalski

JAMA

EMBARGOED FOR RELEASE: 11 A.M. ET, WEDNESDAY, NOVEMBER 13, 2024

Media advisory: The full article is linked to this news release.

Embed this link to provide your readers free access to the full-text article This link will be live at the embargo time https://jamanetwork.com/journals/jama/fullarticle/10.1001/jama.2024.22284?guestAccessKey=7e4684ea-a57e-4064-8d2c-128da03442e7&utm_source=For_The_Media&utm_medium=referral&utm_campaign=ftm_links&utm_content=tfl&utm_term=111324

 

About The Article: This Viewpoint discusses the health benefits of glucagon-like peptide-1 receptor agonists (GLP-1 RAs); summarizes the clinical, policy, and equity implications of GLP-1 RA discontinuation; and calls for the identification and implementation of strategies to improve long-term adherence to GLP-1 RA therapy. 

Corresponding Author: To contact the corresponding author, Sadiya S. Khan, MD, MSc, email s-khan-1@northwestern.edu.

 

(doi:10.1001/jama.2024.22284)

Editor’s Note: Please see the article for additional information, including other authors, author contributions and affiliations, conflict of interest and financial disclosures, and funding and support.

#  #  #

For more information, contact JAMA Network Media Relations at 312-464-JAMA (5262) or email media relations.

No Comments

Filed under:

Medical Board Discipline of Physicians for Spreading Medical Misinformation

Posted by Alexandra Marusarz

JAMA Network Open

EMBARGOED FOR RELEASE: 11 A.M. (ET), TUESDAY, NOVEMBER 12, 2024

Media advisory: The full study is linked to this news release.

Embed this link to provide your readers free access to the full-text article This link will be live at the embargo time http://jamanetwork.com/journals/jamanetworkopen/fullarticle/10.1001/jamanetworkopen.2024.43893?utm_source=For_The_Media&utm_medium=referral&utm_campaign=ftm_links&utm_term=111224

About JAMA Network Open: JAMA Network Open is an online-only open access general medical journal from the JAMA Network. On weekdays, the journal publishes peer-reviewed clinical research and commentary in more than 40 medical and health subject areas. Every article is free online from the day of publication.

 

About The Study: The frequency of discipline for physician-spread misinformation observed in this cross-sectional study was quite low despite increased salience and medical board warnings since the start of the COVID-19 pandemic about the dangers of physicians spreading falsehoods. These findings suggest a serious disconnect between regulatory guidance and enforcement and call into question the suitability of licensure regulation for combatting physician-spread misinformation.

Corresponding author: To contact the corresponding author, Richard S. Saver, J.D., email saver@email.unc.edu.

 

(doi: 10.1001/jamanetworkopen.2024.43893)

Editor’s Note: Please see the article for additional information, including other authors, author contributions and affiliations, conflict of interest and financial disclosures, and funding and support.

#  #  #

For more information, contact JAMA Network Media Relations at 312-464-JAMA (5262) or email media relations.

No Comments

Filed under:

Overtreatment of Prostate Cancer Among Men With Limited Longevity in the Active Surveillance Era

Posted by Jim Michalski

Embed this link to provide your readers free access to the full-text article This link will be live at the embargo time https://jamanetwork.com/journals/jamainternalmedicine/fullarticle/10.1001/jamainternmed.2024.5994?guestAccessKey=b70e9756-4431-4899-aafc-16108a1f7194&utm_source=for_the_media&utm_medium=referral&utm_campaign=ftm_links&utm_content=tfl&utm_term=111124

No Comments

Filed under:

Kidney Transplantation Among Presumed Undocumented Immigrants After Changes in US State Policies

Posted by Jim Michalski

Embed this link to provide your readers free access to the full-text article This link will be live at the embargo time https://jamanetwork.com/journals/jamainternalmedicine/fullarticle/10.1001/jamainternmed.2024.5953?guestAccessKey=e4c9ed39-7bf9-4c80-a32f-52e515f37fa9&utm_source=for_the_media&utm_medium=referral&utm_campaign=ftm_links&utm_content=tfl&utm_term=111124

No Comments

Filed under:

Asthma and Memory Function in Children

Posted by Jim Michalski

JAMA Network Open

EMBARGOED FOR RELEASE: 11 A.M. ET, MONDAY, NOVEMBER 11, 2024

Media advisory: The full study is linked to this news release.

Embed this link to provide your readers free access to the full-text article This link will be live at the embargo time http://jamanetwork.com/journals/jamanetworkopen/fullarticle/10.1001/jamanetworkopen.2024.42803?utm_source=For_The_Media&utm_medium=referral&utm_campaign=ftm_links&utm_term=111124

About JAMA Network Open: JAMA Network Open is an online-only open access general medical journal from the JAMA Network. On weekdays, the journal publishes peer-reviewed clinical research and commentary in more than 40 medical and health subject areas. Every article is free online from the day of publication. 

 

About The Study: In this cohort study, asthma was associated with memory difficulties in children, which may be more severe if asthma onset is earlier in childhood and may extend to executive function abilities. 

Corresponding Author: To contact the corresponding author, Nicholas J. Christopher-Hayes, MA, email nchristopherhayes@ucdavis.edu.

 

(doi:10.1001/jamanetworkopen.2024.42803)

Editor’s Note: Please see the article for additional information, including other authors, author contributions and affiliations, conflict of interest and financial disclosures, and funding and support.

#  #  #

For more information, contact JAMA Network Media Relations at 312-464-JAMA (5262) or email media relations.

No Comments

Filed under:

Prevalence of Adverse Childhood Experiences in Child Population Samples

Posted by Jim Michalski

JAMA Pediatrics

EMBARGOED FOR RELEASE: 11 A.M. (ET), MONDAY, NOVEMBER 11, 2024

Media advisory: The full study is linked to this news release.

Embed this link to provide your readers free access to the full-text article This link will be live at the embargo time https://jamanetwork.com/journals/jamapediatrics/fullarticle/10.1001/jamapediatrics.2024.4385?guestAccessKey=0aac0d29-c18f-4e50-b422-ada01d665b00&utm_source=for_the_media&utm_medium=referral&utm_campaign=ftm_links&utm_content=tfl&utm_term=111124

 

About The Study: In this study, adverse childhood experiences (ACEs), which include abuse, neglect, and family dysfunction, were prevalent among children with notable disparities across participant demographic characteristics and contexts. As principal antecedent threats to child and adolescent well-being that can affect later life prospects, ACEs represent a pressing global social issue. Effective early identification and prevention strategies, including targeted co-designed community interventions, can reduce the prevalence
of ACEs and mitigate their severe effects, thereby minimizing the harmful health consequences of childhood adversity in future generations.

Corresponding Author: To contact the corresponding author, Sheri Madigan, PhD, email sheri.madigan@ucalgary.ca.

 

(doi:10.1001/jamapediatrics.2024.4385)

Editor’s Note: Please see the article for additional information, including other authors, author contributions and affiliations, conflict of interest and financial disclosures, and funding and support.

#  #  #

For more information, contact JAMA Network Media Relations at 312-464-JAMA (5262) or email media relations.

No Comments

Filed under:

Online Retailer Nonadherence to Age Verification, Shipping, and Flavor Restrictions on E-Cigarettes

Posted by Jim Michalski

Embed this link to provide your readers free access to the full-text article This link will be live at the embargo time https://jamanetwork.com/journals/jama/fullarticle/10.1001/jama.2024.21597?guestAccessKey=3b2cc868-20e1-4872-ba6b-46bb36993f37&utm_source=For_The_Media&utm_medium=referral&utm_campaign=ftm_links&utm_content=tfl&utm_term=111124

No Comments

Filed under:

State Divorce Laws, Reproductive Care Policies, and Pregnancy-Associated Homicide Rates

Posted by Jim Michalski

JAMA Network Open

EMBARGOED FOR RELEASE: 11 A.M. ET, FRIDAY, NOVEMBER 8, 2024

Media advisory: The full study is linked to this news release.

Embed this link to provide your readers free access to the full-text article This link will be live at the embargo time http://jamanetwork.com/journals/jamanetworkopen/fullarticle/10.1001/jamanetworkopen.2024.44199?utm_source=For_The_Media&utm_medium=referral&utm_campaign=ftm_links&utm_term=110824

About JAMA Network Open: JAMA Network Open is an online-only open access general medical journal from the JAMA Network. On weekdays, the journal publishes peer-reviewed clinical research and commentary in more than 40 medical and health subject areas. Every article is free online from the day of publication. 

 

About The Study: In this cross-sectional study of pregnancy-associated homicide rates, barriers to divorce were associated with higher homicide rates and access to reproductive health care was associated with lower homicide rates. This study highlights the association between state legislation and pregnancy-associated homicide in the U.S., which is important information for policymakers. 

Corresponding Author: To contact the corresponding author, Kaitlin M. Boyle, PhD, email kb49@mailbox.sc.edu.

 

(doi:10.1001/jamanetworkopen.2024.44199)

Editor’s Note: Please see the article for additional information, including other authors, author contributions and affiliations, conflict of interest and financial disclosures, and funding and support.

#  #  #

For more information, contact JAMA Network Media Relations at 312-464-JAMA (5262) or email media relations.

No Comments

Filed under:

Catastrophic Health Expenditures for In-State and Out-of-State Abortion Care

Posted by Jim Michalski

JAMA Network Open

EMBARGOED FOR RELEASE: 11 A.M. ET, FRIDAY, NOVEMBER 8, 2024

Media advisory: The full study is linked to this news release.

Embed this link to provide your readers free access to the full-text article This link will be live at the embargo time http://jamanetwork.com/journals/jamanetworkopen/fullarticle/10.1001/jamanetworkopen.2024.44146?utm_source=For_The_Media&utm_medium=referral&utm_campaign=ftm_links&utm_term=110824

About JAMA Network Open: JAMA Network Open is an online-only open access general medical journal from the JAMA Network. On weekdays, the journal publishes peer-reviewed clinical research and commentary in more than 40 medical and health subject areas. Every article is free online from the day of publication. 

 

About The Study: In this cross-sectional study of U.S. patients seeking abortion, many individuals and their households were estimated to incur catastrophic health expenditures, particularly those traveling from out of state. The financial and psychological burdens of abortion seeking have likely worsened after the Dobbs decision, as more people need to cross state lines to reach abortion care. The findings suggest expansion of insurance coverage to ensure equitable access to abortion care, irrespective of people’s state of residence, is needed.

Corresponding Author: To contact the corresponding author, Ortal Wasser, MSW, email ow345@nyu.edu.

 

(doi:10.1001/jamanetworkopen.2024.44146)

Editor’s Note: Please see the article for additional information, including other authors, author contributions and affiliations, conflict of interest and financial disclosures, and funding and support.

#  #  #

For more information, contact JAMA Network Media Relations at 312-464-JAMA (5262) or email media relations.

No Comments

Filed under:

Heat Waves and Adverse Health Events Among Dually Eligible Individuals 65 Years and Older

Posted by Jim Michalski

JAMA Health Forum

EMBARGOED FOR RELEASE: 11 A.M. (ET), FRIDAY, NOVEMBER 8, 2024

Media advisory: The full study and commentary are linked to this news release.

Embed this link to provide your readers free access to the full-text article This link will be live at the embargo time https://jamanetwork.com/journals/jama-health-forum/fullarticle/10.1001/jamahealthforum.2024.3884?utm_source=For_The_Media&utm_medium=referral&utm_campaign=ftm_links&utm_term=110824

About JAMA Health Forum: JAMA Health Forum is an international, peer-reviewed, online, open access journal that addresses health policy and strategies affecting medicine, health and health care. The journal publishes original research, evidence-based reports and opinion about national and global health policy; innovative approaches to health care delivery; and health care economics, access, quality, safety, equity and reform. Its distribution will be solely digital and all content will be freely available for anyone to read.

 

About The Study: In this time-series study, heat waves were associated with increased adverse health events among dually eligible individuals 65 years and older. Without adaptation strategies to address the health-related impacts of heat, dually eligible individuals are increasingly likely to face adverse outcomes. 

Corresponding Author: To contact the corresponding author, Hyunjee Kim, PhD, email kihy@ohsu.edu.

 

(doi:10.1001/jamahealthforum.2024.3884)

Editor’s Note: Please see the article for additional information, including other authors, author contributions and affiliations, conflict of interest and financial disclosures, and funding and support.

#  #  #

For more information, contact JAMA Network Media Relations at 312-464-JAMA (5262) or email media relations.

No Comments

Filed under:

Neurodevelopment in the First 2 Years of Life Following Prenatal Exposure to Maternal SARS-CoV-2 Infection

Posted by Jim Michalski

JAMA Network Open

EMBARGOED FOR RELEASE: 11 A.M. ET, THURSDAY, NOVEMBER 7, 2024

Media advisory: The full study is linked to this news release.

Embed this link to provide your readers free access to the full-text article This link will be live at the embargo time http://jamanetwork.com/journals/jamanetworkopen/fullarticle/10.1001/jamanetworkopen.2024.43697?utm_source=For_The_Media&utm_medium=referral&utm_campaign=ftm_links&utm_term=110724

About JAMA Network Open: JAMA Network Open is an online-only open access general medical journal from the JAMA Network. On weekdays, the journal publishes peer-reviewed clinical research and commentary in more than 40 medical and health subject areas. Every article is free online from the day of publication. 

 

About The Study: In this longitudinal cohort study of multiple aspects of child neurodevelopment between ages 6 and 24 months, negligible associations between prenatal exposure to SARS-CoV-2 infection and child outcomes were observed. Follow-up research is warranted to determine whether these predominantly null effects persist into later childhood.

Corresponding Author: To contact the corresponding author, Gerald F. Giesbrecht, PhD, email ggiesbre@ucalgary.ca.

 

(doi:10.1001/jamanetworkopen.2024.43697)

Editor’s Note: Please see the article for additional information, including other authors, author contributions and affiliations, conflict of interest and financial disclosures, and funding and support.

#  #  #

For more information, contact JAMA Network Media Relations at 312-464-JAMA (5262) or email media relations.

No Comments

Filed under:

Racial Disparities in Genetic Detection Rates for Inherited Retinal Diseases

Posted by Jim Michalski

JAMA Ophthalmology

EMBARGOED FOR RELEASE: 11 A.M. (ET), THURSDAY, NOVEMBER 7, 2024

Media advisory: The full study is linked to this news release.

Embed this link to provide your readers free access to the full-text article This link will be live at the embargo time https://jamanetwork.com/journals/jamaophthalmology/fullarticle/10.1001/jamaophthalmol.2024.4696?guestAccessKey=9f18f36f-3b0d-4b0e-9fa5-55edea1f9afc&utm_source=For_The_Media&utm_medium=referral&utm_campaign=ftm_links&utm_content=tfl&utm_term=110724

 

About The Study: Results from this study highlight a lower genetic detection rate for Black patients than for white patients with inherited retinal diseases. This supports a concern that the current development of inherited retinal disease therapeutics is highly dependent on the ability to identify the genetic cause of disease.

Corresponding Author: To contact the corresponding author, K. Thiran Jayasundera, M.D., email thiran@med.umich.edu.

 

(doi:10.1001/jamaophthalmol.2024.4696)

Editor’s Note: Please see the article for additional information, including other authors, author contributions and affiliations, conflict of interest and financial disclosures, and funding and support.

#  #  #

For more information, contact JAMA Network Media Relations at 312-464-JAMA (5262) or email media relations.

No Comments

Filed under:

Long-Term Adverse Effects and Complications After Prostate Cancer Treatment

Posted by Jim Michalski

Embed this link to provide your readers free access to the full-text article This link will be live at the embargo time https://jamanetwork.com/journals/jamaoncology/fullarticle/10.1001/jamaoncol.2024.4397?guestAccessKey=13ba5074-e095-494d-bf0f-6891098e9a69&utm_source=For_The_Media&utm_medium=referral&utm_campaign=ftm_links&utm_content=tfl&utm_term=110724

No Comments

Filed under:

Industry Payments to Physicians by Competing Manufacturers Within Novel Therapeutic Classes

Posted by Jim Michalski

Embed this link to provide your readers free access to the full-text article This link will be live at the embargo time https://jamanetwork.com/journals/jama/fullarticle/10.1001/jama.2024.20842?guestAccessKey=9d5a3ef6-4680-4bf2-9bfe-536b21ce9aed&utm_source=For_The_Media&utm_medium=referral&utm_campaign=ftm_links&utm_content=tfl&utm_term=110724

No Comments

Filed under:

Psychosis Spectrum Symptoms Before and After Adolescent Cannabis Use Initiation

Posted by Jim Michalski

Embed this link to provide your readers free access to the full-text article This link will be live at the embargo time https://jamanetwork.com/journals/jamapsychiatry/fullarticle/10.1001/jamapsychiatry.2024.3525?guestAccessKey=093e49cd-cd51-4e17-8db5-7bcddccd710c&utm_source=for_the_media&utm_medium=referral&utm_campaign=ftm_links&utm_content=tfl&utm_term=110624

No Comments

Filed under:

Neuroinflammation, Stress-Related Suicidal Ideation, and Negative Mood in Depression

Posted by Jim Michalski

Embed this link to provide your readers free access to the full-text article This link will be live at the embargo time https://jamanetwork.com/journals/jamapsychiatry/fullarticle/10.1001/jamapsychiatry.2024.3543?guestAccessKey=3aa4acf9-db5b-43a7-a354-5ebf7bffc0eb&utm_source=for_the_media&utm_medium=referral&utm_campaign=ftm_links&utm_content=tfl&utm_term=110624

No Comments

Filed under:

Racial and Ethnic Disparities in Fentanyl and Polysubstance Overdose Deaths

Posted by Jim Michalski

Embed this link to provide your readers free access to the full-text article This link will be live at the embargo time https://jamanetwork.com/journals/jamapsychiatry/fullarticle/10.1001/jamapsychiatry.2024.3435?guestAccessKey=1306dc3e-ecfc-4096-a2ca-8df80c6583df&utm_source=for_the_media&utm_medium=referral&utm_campaign=ftm_links&utm_content=tfl&utm_term=110624

No Comments

Filed under:

Long-Term Risk of Autoimmune and Autoinflammatory Connective Tissue Disorders Following COVID-19

Posted by Jim Michalski

JAMA Dermatology

EMBARGOED FOR RELEASE: 11 A.M. (ET), WEDNESDAY, NOVEMBER 6, 2024

Media advisory: The full study and editorial are linked to this news release.

Embed this link to provide your readers free access to the full-text article This link will be live at the embargo time https://jamanetwork.com/journals/jamadermatology/fullarticle/10.1001/jamadermatol.2024.4233?guestAccessKey=c58e0ba8-9aa0-457e-a4e7-c043439b3e52&utm_source=for_the_media&utm_medium=referral&utm_campaign=ftm_links&utm_content=tfl&utm_term=110624

 

About The Study: This retrospective cohort study with an extended follow-up period found associations between COVID-19 and the long-term risk of various autoimmune and autoinflammatory connective tissue disorders. Long-term monitoring and care of patients is crucial after COVID-19, considering demographic factors, disease severity, and vaccination status, to mitigate these risks.

Corresponding Author: To contact the corresponding author, Solam Lee, MD, PhD, email solam@yonsei.ac.kr.

 

(doi:10.1001/jamadermatol.2024.4233)

Editor’s Note: Please see the article for additional information, including other authors, author contributions and affiliations, conflict of interest and financial disclosures, and funding and support.

#  #  #

For more information, contact JAMA Network Media Relations at 312-464-JAMA (5262) or email media relations.

No Comments

Filed under:

Safety of Simultaneous vs Sequential mRNA COVID-19 and Inactivated Influenza Vaccines

Posted by Jim Michalski

JAMA Network Open

EMBARGOED FOR RELEASE: 11 A.M. ET, WEDNESDAY, NOVEMBER 6, 2024

Media advisory: The full study is linked to this news release.

Embed this link to provide your readers free access to the full-text article This link will be live at the embargo time http://jamanetwork.com/journals/jamanetworkopen/fullarticle/10.1001/jamanetworkopen.2024.43166?utm_source=For_The_Media&utm_medium=referral&utm_campaign=ftm_links&utm_term=110624

About JAMA Network Open: JAMA Network Open is an online-only open access general medical journal from the JAMA Network. On weekdays, the journal publishes peer-reviewed clinical research and commentary in more than 40 medical and health subject areas. Every article is free online from the day of publication. 

 

About The Study: In this randomized clinical trial assessing simultaneous vs sequential administration of mRNA COVID-19 and inactivated influenza vaccines, reactogenicity was comparable in both groups. These findings support the option of simultaneous administration of these vaccines. 

Corresponding Author: To contact the corresponding author, Emmanuel B. Walter, MD, MPH, email chip.walter@duke.edu.

 

(doi:10.1001/jamanetworkopen.2024.43166)

Editor’s Note: Please see the article for additional information, including other authors, author contributions and affiliations, conflict of interest and financial disclosures, and funding and support.

#  #  #

For more information, contact JAMA Network Media Relations at 312-464-JAMA (5262) or email media relations.

No Comments

Filed under:

Global Disparities of Cancer and Its Projected Burden in 2050

Posted by Alexandra Marusarz

JAMA Network Open

EMBARGOED FOR RELEASE: 11 A.M. (ET), TUESDAY, NOVEMBER 5, 2024

Media advisory: The full study is linked to this news release.

Embed this link to provide your readers free access to the full-text article This link will be live at the embargo time http://jamanetwork.com/journals/jamanetworkopen/fullarticle/10.1001/jamanetworkopen.2024.43198?utm_source=For_The_Media&utm_medium=referral&utm_campaign=ftm_links&utm_term=110524

About JAMA Network Open: JAMA Network Open is an online-only open access general medical journal from the JAMA Network. On weekdays, the journal publishes peer-reviewed clinical research and commentary in more than 40 medical and health subject areas. Every article is free online from the day of publication.

 

About The Study: In this cross-sectional study based on data from 2022, cancer disparities were evident across Human Development Index, geographic regions, age, and sex, with further widening projected by 2050. These findings suggest that strengthening access to and quality of health care, including universal health insurance coverage, is key to providing evidence-based cancer prevention, diagnostics, and care.

Corresponding author: To contact the corresponding author, Habtamu Mellie Bizuayehu, Ph.D., M.P.H., email hmba2003@gmail.com.

 

(doi: 10.1001/jamanetworkopen.2024.43198)

Editor’s Note: Please see the article for additional information, including other authors, author contributions and affiliations, conflict of interest and financial disclosures, and funding and support.

#  #  #

For more information, contact JAMA Network Media Relations at 312-464-JAMA (5262) or email media relations.

No Comments

Filed under:

Nurse Burnout and Patient Safety, Satisfaction, and Quality of Care

Posted by Alexandra Marusarz

JAMA Network Open

EMBARGOED FOR RELEASE: 11 A.M. (ET), TUESDAY, NOVEMBER 5, 2024

Media advisory: The full study is linked to this news release.

Embed this link to provide your readers free access to the full-text article This link will be live at the embargo time http://jamanetwork.com/journals/jamanetworkopen/fullarticle/10.1001/jamanetworkopen.2024.43059?utm_source=For_The_Media&utm_medium=referral&utm_campaign=ftm_links&utm_term=110524

About JAMA Network Open: JAMA Network Open is an online-only open access general medical journal from the JAMA Network. On weekdays, the journal publishes peer-reviewed clinical research and commentary in more than 40 medical and health subject areas. Every article is free online from the day of publication.

 

About The Study: Nurse burnout was found to be associated with lower health care quality and safety and lower patient satisfaction in this systematic review and meta-analysis. This association was consistent across nurse and study characteristics.

Corresponding author: To contact the corresponding author, Peilin Yang, B.S., email peilin.yang@upf.edu.

 

(doi: 10.1001/jamanetworkopen.2024.43059)

Editor’s Note: Please see the article for additional information, including other authors, author contributions and affiliations, conflict of interest and financial disclosures, and funding and support.

#  #  #

For more information, contact JAMA Network Media Relations at 312-464-JAMA (5262) or email media relations.

No Comments

Filed under:

Screen Time Before 2 Years of Age and Risk of Autism at 12 Years of Age

Posted by Jim Michalski

Embed this link to provide your readers free access to the full-text article This link will be live at the embargo time https://jamanetwork.com/journals/jamapediatrics/fullarticle/10.1001/jamapediatrics.2024.4432?guestAccessKey=0ac3f988-c80c-43a8-af54-57fb34043c1a&utm_source=For_The_Media&utm_medium=referral&utm_campaign=ftm_links&utm_content=tfl&utm_term=110424

No Comments

Filed under:

A Digital Health Behavior Intervention to Prevent Childhood Obesity

Posted by Jim Michalski

JAMA

EMBARGOED FOR RELEASE: 5:30 P.M. ET, SUNDAY, NOVEMBER 3, 2024

Media advisory: The full study is linked to this news release. This study is being presented at the Obesity Society Conference, ObesityWeek.

Embed this link to provide your readers free access to the full-text article This link will be live at the embargo time https://jamanetwork.com/journals/jama/fullarticle/10.1001/jama.2024.22362?guestAccessKey=718ecc07-ada5-431f-a301-60824022ecfb&utm_source=For_The_Media&utm_medium=referral&utm_campaign=ftm_links&utm_content=tfl&utm_term=110324

 

About The Study: A health literacy-informed digital intervention improved child weight-for-length trajectory across the first 24 months of life and reduced childhood obesity at 24 months. The intervention was effective in a racially and ethnically diverse population that included groups at elevated risk for childhood obesity. 

Corresponding Author: To contact the corresponding author, William J. Heerman, MD, MPH, email Bill.Heerman@vumc.org.

 

(doi:10.1001/jama.2024.22362)

Editor’s Note: Please see the article for additional information, including other authors, author contributions and affiliations, conflict of interest and financial disclosures, and funding and support.

#  #  #

For more information, contact JAMA Network Media Relations at 312-464-JAMA (5262) or email media relations.

No Comments

Filed under:

Translational Science Reviews—A New JAMA Review

Posted by Jim Michalski

JAMA

EMBARGOED FOR RELEASE: 11 A.M. ET, MONDAY, NOVEMBER 4, 2024

Media advisory: The editor’s note is linked to this news release.

Embed this link to provide your readers free access to the full-text article This link will be live at the embargo time https://jamanetwork.com/journals/jama/fullarticle/10.1001/jama.2024.21146?guestAccessKey=8b03f724-5d87-4716-9d6f-34e5350d8472&utm_source=For_The_Media&utm_medium=referral&utm_campaign=ftm_links&utm_content=tfl&utm_term=110424

 

About The Article: To help clinicians keep up with ongoing basic and translational science discoveries that affect the diagnosis and treatment of human disease, JAMA has launched a new series, “Translational Science Reviews.” These new article types are succinct and informative summaries of important basic science advances that are transforming diagnosis and treatment of human disease. 

Corresponding Author: To contact the corresponding author, Mary M. McDermott, MD, email mdm608@northwestern.edu.

 

(doi:10.1001/jama.2024.21146)

Editor’s Note: Please see the article for additional information, including other authors, author contributions and affiliations, conflict of interest and financial disclosures, and funding and support.

#  #  #

For more information, contact JAMA Network Media Relations at 312-464-JAMA (5262) or email media relations.

No Comments

Filed under:

Hospital COVID-19 Burden and Adverse Event Rates

Posted by Jim Michalski

JAMA Network Open

EMBARGOED FOR RELEASE: 11 A.M. ET, MONDAY, NOVEMBER 4, 2024

Media advisory: The full study and commentary are linked to this news release.

Embed this link to provide your readers free access to the full-text article This link will be live at the embargo time http://jamanetwork.com/journals/jamanetworkopen/fullarticle/10.1001/jamanetworkopen.2024.42936?utm_source=For_The_Media&utm_medium=referral&utm_campaign=ftm_links&utm_term=110424

About JAMA Network Open: JAMA Network Open is an online-only open access general medical journal from the JAMA Network. On weekdays, the journal publishes peer-reviewed clinical research and commentary in more than 40 medical and health subject areas. Every article is free online from the day of publication. 

 

About The Study: In this cohort study of hospital admissions among Medicare patients during the COVID-19 pandemic, greater hospital COVID-19 burden was associated with an increased risk of in-hospital adverse effects among both patients with and without COVID-19. These results illustrate the need for greater hospital resilience and surge capacity to prevent declines in patient safety during surges in demand. 

Corresponding Author: To contact the corresponding author, Mark L. Metersky, MD, email metersky@uchc.edu.

 

(doi:10.1001/jamanetworkopen.2024.42936)

Editor’s Note: Please see the article for additional information, including other authors, author contributions and affiliations, conflict of interest and financial disclosures, and funding and support.

#  #  #

For more information, contact JAMA Network Media Relations at 312-464-JAMA (5262) or email media relations.

No Comments

Filed under:

Cannabis Use During Early Pregnancy Following Recreational Cannabis Legalization

Posted by Jim Michalski

JAMA Health Forum

EMBARGOED FOR RELEASE: 11 A.M. (ET), FRIDAY, NOVEMBER 1, 2024

Media advisory: The full study is linked to this news release.

Embed this link to provide your readers free access to the full-text article This link will be live at the embargo time https://jamanetwork.com/journals/jama-health-forum/fullarticle/10.1001/jamahealthforum.2024.3656?utm_source=For_The_Media&utm_medium=referral&utm_campaign=ftm_links&utm_term=110124

About JAMA Health Forum: JAMA Health Forum is an international, peer-reviewed, online, open access journal that addresses health policy and strategies affecting medicine, health and health care. The journal publishes original research, evidence-based reports and opinion about national and global health policy; innovative approaches to health care delivery; and health care economics, access, quality, safety, equity and reform. Its distribution will be solely digital and all content will be freely available for anyone to read.

 

About The Study: In this time-series study, recreational cannabis legalization implementation in California was associated with an increase in rates of cannabis use during early pregnancy, defined by both self-report and toxicology testing, driven by individuals living in jurisdictions that allowed adult-use retailers.

Corresponding Author: To contact the corresponding author, Kelly C. Young-Wolff, PhD, MPH, email kelly.c.young-wolff@kp.org.

 

(doi:10.1001/jamahealthforum.2024.3656)

Editor’s Note: Please see the article for additional information, including other authors, author contributions and affiliations, conflict of interest and financial disclosures, and funding and support.

#  #  #

For more information, contact JAMA Network Media Relations at 312-464-JAMA (5262) or email media relations.

No Comments

Filed under:

Smoking Cessation and Incident Cardiovascular Disease

Posted by Jim Michalski

JAMA Network Open

EMBARGOED FOR RELEASE: 11 A.M. ET, FRIDAY, NOVEMBER 1, 2024

Media advisory: The full study is linked to this news release.

Embed this link to provide your readers free access to the full-text article This link will be live at the embargo time http://jamanetwork.com/journals/jamanetworkopen/fullarticle/10.1001/jamanetworkopen.2024.42639?utm_source=For_The_Media&utm_medium=referral&utm_campaign=ftm_links&utm_term=110124

About JAMA Network Open: JAMA Network Open is an online-only open access general medical journal from the JAMA Network. On weekdays, the journal publishes peer-reviewed clinical research and commentary in more than 40 medical and health subject areas. Every article is free online from the day of publication. 

 

About The Study: In this cohort study, smoking and cardiovascular disease (CVD) risk exhibited a dose-dependent association, with light ex-smokers having a CVD risk similar to that of never-smokers relatively soon after smoking cessation. For heavy ex-smokers, greater than 25 years might be required for the residual CVD risk to align with that of never-smokers. 

Corresponding Author: To contact the corresponding author, Seung Yong Shin, MD, PhD, email theshin04@korea.ac.kr.

 

(doi:10.1001/jamanetworkopen.2024.42639)

Editor’s Note: Please see the article for additional information, including other authors, author contributions and affiliations, conflict of interest and financial disclosures, and funding and support.

#  #  #

For more information, contact JAMA Network Media Relations at 312-464-JAMA (5262) or email media relations.

No Comments

Filed under:

Alzheimer Disease as a Clinical-Biological Construct— An International Working Group Recommendation

Posted by Jim Michalski

JAMA Neurology

EMBARGOED FOR RELEASE: 3:30 A.M. (ET), FRIDAY, NOVEMBER 1, 2024

Media advisory: The full study and editorial are linked to this news release. This study is being presented at the 17th Clinical Trials on Alzheimer’s Disease conference.

Embed this link to provide your readers free access to the full-text article This link will be live at the embargo time https://jamanetwork.com/journals/jamaneurology/fullarticle/10.1001/jamaneurol.2024.3770?guestAccessKey=5d249549-8367-4844-b4c4-b4b21eac4863&utm_source=for_the_media&utm_medium=referral&utm_campaign=ftm_links&utm_content=tfl&utm_term=110124

 

About The Study: This article discusses a recent revision of the Alzheimer Association criteria to define Alzheimer disease (AD) as a purely biological entity, which raises concerns that if diagnosis of AD can be reduced to the sole presence of AD core 1 biomarkers, major uncertainty and variability in the clinical prognosis of patients diagnosed with AD may be introduced.

Corresponding Author: To contact the corresponding author, Bruno Dubois, MD, MSc, email bruno.dubois@aphp.fr.

 

(doi:10.1001/jamaneurol.2024.3770)

Editor’s Note: Please see the article for additional information, including other authors, author contributions and affiliations, conflict of interest and financial disclosures, and funding and support.

#  #  #

For more information, contact JAMA Network Media Relations at 312-464-JAMA (5262) or email media relations.

No Comments

Filed under:

Survival Outcomes of an Early Intervention Smoking Cessation Treatment After a Cancer Diagnosis

Posted by Jim Michalski

JAMA Oncology

EMBARGOED FOR RELEASE: 11 A.M. (ET), THURSDAY, OCTOBER 31, 2024

Media advisory: The full study is linked to this news release.

Embed this link to provide your readers free access to the full-text article This link will be live at the embargo time https://jamanetwork.com/journals/jamaoncology/fullarticle/10.1001/jamaoncol.2024.4890?guestAccessKey=a03150b0-0509-4304-a744-c5c6c5626702&utm_source=For_The_Media&utm_medium=referral&utm_campaign=ftm_links&utm_content=tfl&utm_term=103124

 

About The Study: The results of this prospective cohort study suggest that evidence-based smoking cessation treatment within 6 months following a cancer diagnosis maximizes survival benefit. This study supports smoking cessation as an important early clinical intervention for patients after being diagnosed with cancer. 

Corresponding Author: To contact the corresponding author, Paul M. Cinciripini, PhD, email pcinciri@mdanderson.org.

 

(doi:10.1001/jamaoncol.2024.4890)

Editor’s Note: Please see the article for additional information, including other authors, author contributions and affiliations, conflict of interest and financial disclosures, and funding and support.

#  #  #

For more information, contact JAMA Network Media Relations at 312-464-JAMA (5262) or email media relations.

No Comments

Filed under:

Differences in Drug Shortages in the US and Canada

Posted by Jim Michalski

JAMA

EMBARGOED FOR RELEASE: 11 A.M. ET, THURSDAY, OCTOBER 31, 2024

Media advisory: The full study and editor’s note are linked to this news release.

Embed this link to provide your readers free access to the full-text article This link will be live at the embargo time https://jamanetwork.com/journals/jama/fullarticle/10.1001/jama.2024.17688?guestAccessKey=45d5ebdb-f880-4f40-8e06-3719a132643d&utm_source=For_The_Media&utm_medium=referral&utm_campaign=ftm_links&utm_content=tfl&utm_term=103124

 

About The Study: Drug-related reports of supply chain issues were 40% less likely to result in meaningful drug shortages in Canada compared with the U.S. These findings highlight the need for international cooperation between countries to curb the effects of drug shortages and improve resiliency of the supply chain for drugs.

 

Quote from corresponding author Katie J. Suda, PharmD, MS:

“Our U.S. drug supply chain is linked globally – shortages in one country can happen in another country – presenting an opportunity to compare and contrast how different countries are affected. When we compared the U.S. to Canada for drugs with the same supply chain issues, Canada was 40% less likely to experience national drug shortages than the U.S.

“The U.S. can learn from other countries’ pharmaceutical policy to mitigate the impact of shortages on access to essential medications. We also need to cooperate locally and globally to strengthen our pharmaceutical supply chain and regionally to recognize the interconnectedness of supply chains essential for North American health security.”

 

Contact information for Katie J. Suda, PharmD, MS: email Liz Reid at reide4@upmc.edu.

 

(doi:10.1001/jama.2024.17688)

Editor’s Note: Please see the article for additional information, including other authors, author contributions and affiliations, conflict of interest and financial disclosures, and funding and support.

#  #  #

For more information, contact JAMA Network Media Relations at 312-464-JAMA (5262) or email media relations.

No Comments

Filed under:

PTSD, Obesity, and Accelerated Epigenetic Aging Among US Military Veterans

Posted by Jim Michalski

Embed this link to provide your readers free access to the full-text article This link will be live at the embargo time https://jamanetwork.com/journals/jamapsychiatry/fullarticle/10.1001/jamapsychiatry.2024.3403?guestAccessKey=eb8f82f6-795a-4681-adfe-a448467f7d9d&utm_source=for_the_media&utm_medium=referral&utm_campaign=ftm_links&utm_content=tfl&utm_term=103024

No Comments

Filed under:

Slowing Cognitive Decline in Major Depressive Disorder and Mild Cognitive Impairment

Posted by Jim Michalski

JAMA Psychiatry

EMBARGOED FOR RELEASE: 11 A.M. (ET), WEDNESDAY, OCTOBER 30, 2024

Media advisory: The full study is linked to this news release.

Embed this link to provide your readers free access to the full-text article This link will be live at the embargo time https://jamanetwork.com/journals/jamapsychiatry/fullarticle/10.1001/jamapsychiatry.2024.3241?guestAccessKey=25ef487c-b5bd-4cbe-aaca-da718af2b402&utm_source=for_the_media&utm_medium=referral&utm_campaign=ftm_links&utm_content=tfl&utm_term=103024

 

About The Study: This study showed that cognitive remediation and transcranial direct current stimulation, both targeting the prefrontal cortex, is efficacious in slowing cognitive decline in older adults at risk of cognitive decline, particularly those with remitted major depressive disorder (with or without mild cognitive impairment) and in those at low genetic risk for Alzheimer disease. 

Corresponding Author: To contact the corresponding authors, email Benoit H. Mulsant, MD, MS, (benoit.mulsant@utoronto.ca) and Tarek K. Rajji, MD, (tarek.rajji@utsouthwestern.edu)

 

(10.1001/jamapsychiatry.2024.3241)

Editor’s Note: Please see the article for additional information, including other authors, author contributions and affiliations, conflict of interest and financial disclosures, and funding and support.

#  #  #

For more information, contact JAMA Network Media Relations at 312-464-JAMA (5262) or email media relations.

No Comments

Filed under:

Autism Diagnosis Among US Children and Adults

Posted by Jim Michalski

JAMA Network Open

EMBARGOED FOR RELEASE: 11 A.M. ET, WEDNESDAY, OCTOBER 30, 2024

Media advisory: The full study is linked to this news release.

Embed this link to provide your readers free access to the full-text article This link will be live at the embargo time http://jamanetwork.com/journals/jamanetworkopen/fullarticle/10.1001/jamanetworkopen.2024.42218?utm_source=For_The_Media&utm_medium=referral&utm_campaign=ftm_links&utm_term=103024

About JAMA Network Open: JAMA Network Open is an online-only open access general medical journal from the JAMA Network. On weekdays, the journal publishes peer-reviewed clinical research and commentary in more than 40 medical and health subject areas. Every article is free online from the day of publication. 

 

About The Study: In this cross-sectional study of children and adults in the U.S., autism spectrum disorder diagnosis rates increased substantially between 2011 and 2022, particularly among young adults, female children and adults, and children from some racial or ethnic minority groups. Diagnosis prevalence trends generated using health system data can inform the allocation of resources to meet the service needs of this growing, medically complex population.

Corresponding Author: To contact the corresponding author, Luke P. Grosvenor, PhD, email luke.p.grosvenor@kp.org.

 

(doi:10.1001/jamanetworkopen.2024.42218)

Editor’s Note: Please see the article for additional information, including other authors, author contributions and affiliations, conflict of interest and financial disclosures, and funding and support.

#  #  #

For more information, contact JAMA Network Media Relations at 312-464-JAMA (5262) or email media relations.

No Comments

Filed under:

State Policies Regulating Law Enforcement Access to Prescription Drug Monitoring Program Testosterone Prescription Data

Posted by Jim Michalski

JAMA

EMBARGOED FOR RELEASE: 11 A.M. ET, WEDNESDAY, OCTOBER 30, 2024

Media advisory: The full study is linked to this news release.

Embed this link to provide your readers free access to the full-text article This link will be live at the embargo time https://jamanetwork.com/journals/jama/fullarticle/10.1001/jama.2024.20035?guestAccessKey=7aec6623-446c-4b34-a47b-0e07cd0c7a5f&utm_source=For_The_Media&utm_medium=referral&utm_campaign=ftm_links&utm_content=tfl&utm_term=103024

 

About The Study: This study found that testosterone prescription data through prescription drug monitoring programs was accessible to law enforcement without basic safeguards (such as a warrant or subpoena) in nearly half of states. The ease of access to this sensitive medical information raises privacy, care quality, and civil liberties concerns, especially amid the proliferation of gender-affirming care bans.

Corresponding Author: To contact the corresponding author, Katie McCreedy, MPH, email mccreedy.k@northeastern.edu.

 

(doi:10.1001/jama.2024.20035)

Editor’s Note: Please see the article for additional information, including other authors, author contributions and affiliations, conflict of interest and financial disclosures, and funding and support.

#  #  #

For more information, contact JAMA Network Media Relations at 312-464-JAMA (5262) or email media relations.

No Comments

Filed under:

Early Intervention in Patients With Asymptomatic Severe Aortic Stenosis and Myocardial Fibrosis

Posted by Jim Michalski

JAMA

EMBARGOED FOR RELEASE: 11:20 A.M. ET, MONDAY, OCTOBER 28, 2024

Media advisory: The full study and editorial are linked to this news release. This study is being presented at TCT 2024.

Embed this link to provide your readers free access to the full-text article This link will be live at the embargo time https://jamanetwork.com/journals/jama/fullarticle/10.1001/jama.2024.22730?guestAccessKey=1ceacfdf-69b0-46ec-a184-624f63ed513b&utm_source=For_The_Media&utm_medium=referral&utm_campaign=ftm_links&utm_content=tfl&utm_term=102824

 

About The Study: In asymptomatic patients with severe aortic stenosis and myocardial fibrosis, early aortic valve intervention had no demonstrable effect on all-cause death or unplanned aortic stenosis–related hospitalization. The trial had a wide 95% CI around the primary end point, with further research needed to confirm these findings.

Corresponding Author: To contact the corresponding author, Marc R. Dweck, PhD, email marc.dweck@ed.ac.uk.

 

(doi:10.1001/jama.2024.22730)

Editor’s Note: Please see the article for additional information, including other authors, author contributions and affiliations, conflict of interest and financial disclosures, and funding and support.

#  #  #

For more information, contact JAMA Network Media Relations at 312-464-JAMA (5262) or email media relations.

No Comments

Filed under:

Inhaled Reliever Therapies for Asthma

Posted by Jim Michalski

JAMA

EMBARGOED FOR RELEASE: 8 A.M. ET, MONDAY, OCTOBER 28, 2024

Media advisory: The full study is linked to this news release. This study is being presented at the American College of Allergy, Asthma & Immunology’s Annual Scientific Meeting.

Embed this link to provide your readers free access to the full-text article This link will be live at the embargo time https://jamanetwork.com/journals/jama/fullarticle/10.1001/jama.2024.22700?guestAccessKey=dd710369-e153-4cee-b56d-c9c93d5ecf22&utm_source=For_The_Media&utm_medium=referral&utm_campaign=ftm_links&utm_content=tfl&utm_term=102824

 

About The Study: In this network meta-analysis of patients with asthma, inhaled corticosteroids combined with formoterol and inhaled corticosteroids combined with short-acting β agonists were each associated with reduced asthma exacerbations and improved asthma control compared with short-acting β agonists alone.

Corresponding Author: To contact the corresponding author, Derek K. Chu, MD, PhD, email chudk@mcmaster.ca.

 

(doi:10.1001/jama.2024.22700)

Editor’s Note: Please see the article for additional information, including other authors, author contributions and affiliations, conflict of interest and financial disclosures, and funding and support.

#  #  #

For more information, contact JAMA Network Media Relations at 312-464-JAMA (5262) or email media relations.

No Comments

Filed under:

Validation of the Kansas City Cardiomyopathy Questionnaire in Patients With Tricuspid Regurgitation

Posted by Jim Michalski

JAMA Cardiology

EMBARGOED FOR RELEASE: 11 A.M. (ET), WEDNESDAY, OCTOBER 30, 2024

Media advisory: The full study and commentary are linked to this news release. This study is being presented at TCT 2024.

Embed this link to provide your readers free access to the full-text article This link will be live at the embargo time https://jamanetwork.com/journals/jamacardiology/fullarticle/10.1001/jamacardio.2024.4266?guestAccessKey=1ba6a510-a25d-4fe3-b356-948ff8eed4b5&utm_source=for_the_media&utm_medium=referral&utm_campaign=ftm_links&utm_content=tfl&utm_term=103024

 

About The Study: In this cohort study, the Kansas City Cardiomyopathy Questionnaire (KCCQ) had strong psychometric properties in patients with severe tricuspid regurgitation, including reliability, responsiveness, and validity. These data support use of the KCCQ in patients with severe tricuspid regurgitation as a measure of their symptoms, function, and quality of life and also for assessing the impact of interventions, such as transcatheter tricuspid valve intervention, in rigorously controlled trials. 

Corresponding Author: To contact the corresponding author, Suzanne V. Arnold, MD, MHA, email sarnold@saint-lukes.org.

 

(doi:10.1001/jamacardio.2024.4266)

Editor’s Note: Please see the article for additional information, including other authors, author contributions and affiliations, conflicts of interest and financial disclosures, and funding and support.

#  #  #

For more information, contact JAMA Network Media Relations at 312-464-JAMA (5262) or email media relations.

No Comments

Filed under: